Skip to content

Encycle Therapeutics raises $2.85 million to advance macrocycle platform and pipeline

Encycle TherapeuticsTORONTO, ON (September 30, 2015) — Encycle Therapeutics, Inc., a University of Toronto spin-off company created in partnership with MaRS Innovation, announced today that it has completed a $2.85 million (CAD) financing led by Takeda Pharmaceutical Company Ltd. through its venture capital arm, Takeda Ventures, Inc., with Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund.

This news was covered in PEHub, BetaKit and TechVibes.

The funding will support ongoing development of Encycle’s unique nacellin platform chemistry and advance the company’s pipeline of novel therapeutics. It will also allow the company to build on research collaborations with several pharmaceutical companies and ultimately position it for a series A transaction and/or additional strategic partnerships.

“Our proprietary chemistry has the potential to unlock myriad therapeutic avenues, including via intracellular protein-protein interactions that cannot be targeted with conventional therapeutics,” said Dr. Jeffrey Coull, president and CEO of Encycle Therapeutics; upon the closing, Coull joined Encycle’s board of directions. “This funding is critical to enable the company to further explore the vast potential of our technology and to de-risk it to the extent that major transactions will be enabled.”

“Our goal is to make an impact on patients’ lives by turning science and technology into life-changing medicines. We are enthusiastic about Encycle’s technology and its potential in the context of ‘undruggable’ proteins,” said Dr. Ilan Zipkin, senior investment director at Takeda.

“Encycle’s growing momentum reflects MaRS Innovation’s efforts to shift the Canadian paradigm for technology transfer,” said Dr. Raphael Hofstein, chairman of the Encycle Therapeutics Board of Directors and president and CEO of MaRS Innovation. “This company began with promising research in Dr. Andrei Yudin’s laboratory at the University of Toronto. With crucial support from many players along the Ontario-Quebec life sciences corridor, MaRS Innovation collaborated with him to package and protect the technology, launch the company and hire experienced management. The success of this funding round bodes well for its future growth and success.”

Continue Reading

Financial Post covers Onyx Motion’s Swish app, scheduled to launch in November

Company plans future sports applications for tennis and golf for its Motion Marketplace

Onyx product shotSwish by Onyx Motion “takes advantage of motion sensors to provide accurate tips and feedback to improve play,” wrote Robert Liwanag in “App for smartwatches helps users become better basketball players” for the Financial Post‘s “Entrepreneur” section on September 28, 2015.

“Using it is simple — you turn it on, press calibrate and lift your arms and hands as you would to shoot a basket,” wrote Liwanag. “The objective is to bring the circle hovering inside the target on the watch’s screen to go green. When it does, the user is in the right starting position and has the ability to achieve consistency shot after shot.”

Onyx Motion is a graduate of the UTEST program‘s third cohort (and is currently based in Ryerson’s Digital Media Zone). Their basketball app, which is scheduled to launch in November after a successful Indiegogo campaign, is the first of several sports-focused products planned by CEO Marissa Wu.

Continue Reading

TD announces exclusive Canadian agreement with Flybits

Companies to collaborate on creating enhanced personalized mobile experiences for TD customers

Flybits corporate logo 2015TORONTO, Sept. 16, 2015 — TD Bank Group and Flybits today announced an exclusive agreement within the Canadian financial services industry to collaborate on providing TD customers with more personalized mobile banking experiences.

This announcement was covered in Forbes, BetaKit, TechVibes, IT Business.ca, Marketing Magazine, CAN Tech Letter and Strategy online.

The Flybits cloud-based software program transforms mobile apps to deliver rich, contextual experiences to each user, including personalized financial advice—where and when they need it.

Flybits is a Ryerson University start-up created in partnership with MaRS Innovation. Read more about their growth and development in our news archive.

“A key focus for TD’s digital roadmap is to create more intuitive, personalized experiences that make customers’ lives simpler,” said Rizwan Khalfan, senior vice president and chief digital officer, TD. “Our agreement with Flybits is another example of TD demonstrating its commitment to enriching customers’ lives through innovation. We’re elevating our customer-centric approach by bringing in-the-moment experiences to each individual depending on their situation and needs.”

Continue Reading

Global University Venturing features MaRS Innovation’s unique model for technology transfer

Dr. Raphael Hofstein
Dr. Raphael Hofstein, president & CEO, MaRS Innovation.

MaRS Innovation’s “model solves the two weakest points in tech transfer: the lack of dealflow and the ability to match public funding,” writes Thierry Heles in, “MaRS Innovation: A Unique Model for Tech Transfer,” for Global University Venturing.

This feature was also covered in Techopia.

The article, which includes an interview with Dr. Rafi Hofstein, president and CEO of MaRS Innovation, was published September 14, 2015.

Here’s an excerpt exploring the range of MI’s portfolio and Hofstein’s strategy for addressing technologies emerging in new areas:

In the beginning, Mars received primarily discoveries in the medical sector, but the balance has since shifted to 60% medically-oriented research and 40% for other areas. The medically-oriented discoveries, Hofstein elaborated, are a diverse set of technologies and include everything from drug development and molecular diagnostics to medical devices and healthcare IT.

The remaining 40% meanwhile cover “a smörgåsbord all the way from alternative energies and solar energy, and water reclamation to all sorts of mobile apps”.

Continue Reading

Ontario Government, University of Toronto, and MaRS secure Johnson & Johnson Innovation, JLABS for Toronto – first JLABS Incubator outside of United States

Partners for JLABS @ Toronto include Janssen Inc., MaRS Innovation and seven of MI’s 15 member institutions

 Minister of Economic Development, Employment and Infrastructure Brad Duguid announces the arrival of JLABS @ Toronto in the MaRS Discovery District. First row, left to right: Chris Halyk, president of Janssen Inc.; Melinda Richter, head of JLABS, Johnson & Johnson; Dr. Meric Gertler, president, University of Toronto; Minister Duguid; Dr. Ilse Treuricht, CEO MaRS Discovery District; Dr. Raphael (Rafi) Hofstein, president and CEO MaRS Innovation, and Robert Urban, head of Johnson & Johnson Innovation Boston. Second row: Dr. Robert Howard, president and CEO St. Michael's Hospital; Dr. Catherine Zahn, president and CEO CAMH; Dr. Barry McLellan, president and CEO Sunnybrook Health Sciences Centre; Dr. Peter Pisters, president & CEO University Health Network; Dr. Jim Woddgett, director of research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; and Dr. Michael Apkon, president and CEO, The Hospital for Sick Children.

Minister of Economic Development, Employment and Infrastructure Brad Duguid announces the arrival of JLABS @ Toronto in the MaRS Discovery District. First row, left to right: Chris Halyk, president of Janssen Inc.; Melinda Richter, head of JLABS, Johnson & Johnson; Dr. Meric Gertler, president, University of Toronto; Minister Duguid; Dr. Ilse Treuricht, CEO MaRS Discovery District; Dr. Raphael (Rafi) Hofstein, president and CEO MaRS Innovation, and Robert Urban, head of Johnson & Johnson Innovation Boston. Second row: Dr. Robert Howard, president and CEO St. Michael’s Hospital; Dr. Catherine Zahn, president and CEO CAMH; Dr. Barry McLellan, president and CEO Sunnybrook Health Sciences Centre; Dr. Peter Pisters, president & CEO University Health Network; Dr. Jim Woddgett, director of research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; and Dr. Michael Apkon, president and CEO, The Hospital for Sick Children.

 

TORONTO, Sept. 8, 2015 — The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) today announced a collaboration with Janssen Inc. to launch the successful Johnson & Johnson Innovation, JLABS incubator model in Toronto.

This announcement has been covered in the Toronto Star, Metro News Canada, Sing Tao Daily, OurWindsor.ca, FierceBiotech, BioCentury, MedCity News, BioSpace, Biotechnology Focus, Lab Product News, ChinaNews.com, Pan European Networks, Economic Development Blog, BetaKit, Torontoist, and TechVibes.

It was also featured news on Rx&D‘s and Life Sciences Ontario‘s websites.

The new facility, called JLABS @ Toronto, will open in spring of 2016 at MaRS Discovery District and will support start-ups with lab space, programs, and potential investment partners as they work to build important, successful early-stage companies.

“The arrival of the Johnson & Johnson Innovation, JLABS model to MaRS’ West Tower reinforces Ontario’s position as one of the world’s leading life sciences clusters,” said Brad Duguid, Minister of Economic Development, Employment and Infrastructure. “JLABS @ Toronto will support researchers and entrepreneurs across the province and accelerate the development of Ontario companies while connecting Toronto to potential Johnson & Johnson collaborators and investors.”

“Research and innovation are fundamental to the mission of the University of Toronto,” said Dr. Meric S. Gertler, President, University of Toronto. “We host a vibrant entrepreneurial ecosystem featuring nine campus-led accelerators under the umbrella of our Banting & Best Centre for Innovation and Entrepreneurship. The addition of JLABS to this ecosystem will further propel the creation of new companies and new jobs, and ultimately new healthcare solutions that will benefit individuals and our society for years to come.”

“Toronto is home to a vibrant and prolific healthcare and life sciences community led by academic hospitals, world-class research institutions, top scientists, and a strong start-up ecosystem. For these reasons, Toronto is a natural choice for our first international expansion of JLABS,” said Melinda Richter, Head of JLABS. “The Johnson & Johnson Family of Companies has long been active within the Toronto Ontario community, forming many important collaborations. Today we are pleased to begin an even deeper relationship with this important community. Our new location, within a University of Toronto site, close to our hospital collaborators, and neighbouring the financial centre of Canada, will deliver great opportunities and impact for emerging biomedical technology entrepreneurs.”

Continue Reading

UTEST company Nvest listed in Omers’ Canadian #FinTech Infographic

Nvest Logo“Over the past few weeks, a few members of our investment team took the seopportunity to map out FinTech companies from coast-to-coast, focusing on those that are developing next generation technologies or technology enabled services,” wrote the OMERS Venture team in a blog post accompanying a new #fintech infographic that lists 89 Canadian businesses operating in the financial start-up sector.

Nvest, part of the third UTEST cohort, in included in the graphic (see below). The infographic’s release was also covered in BetaKit in a story by Doug Soltys noting the sector’s growth in just six months:

What a difference six months makes. Today, Canadian VC giant OMERS Ventures released a similar infographic, tracking 89 different Canadian FinTech startups from Vancouver to St. John’s, essentially a 40 per cent increase. OMERS also noted that these 89 companies have attracted over $1 billion in capital since 2010.

Here’s where OMERS Ventures’ take on where the sector going:

Continue Reading

My Virtual Dream publishes PLOS study on Nuit Blanche results

“My Virtual Dream” is an innovative and interactive live performance experience of the Virtual Brain technology developed by researchers at Baycrest Health Sciences Centre in partnership with neuroscience experts around the world.

Baycrest Heath Sciences’ “My Virtual Dream,” an innovative and interactive live performance experience at the intersection of science, art and music, is currently touring the installation with appearances in Amsterdam in May and more scheduled for Irvine, CA in October.

MaRS Innovation is working with the Baycrest team to commercialize the technology behind the demonstration, known as the virtual brain.

My Virtual Dream was featured in TechVibes on July 8 and in a PLOS blog published on August 14, 2015.

“The Virtual Dream tour is a ‘living lab’ that engages the public, fuels science, creates art and educates while it entertains,” says Richard Tavener, executive producer of the Virtual Dream tour.

The exhibition and research project was originally mounted in partnership with the University of Toronto, Nuit Blanche 2013, and InteraXon and also made a January 2015 appearance at the Ontario Science Centre.

Participants wear the Muse, a brain-computer interface headset provided by InteraXon, and use focus and mental relaxation states to complete a science game and create a stunning array of visuals and music.

The brain data collected at Nuit Blanche has yielded insights about how the brain learns and a science paper about this massive, one-night neuroscience experiment. The paper, which appeared in the July issue of PLOS One, found that:

Continue Reading

LegWorks takes top spot at Parapan Am accessibility tech pitch contest

BresoTec, formerly known as ApneaDx, also among top five finalists

LegWorks LogoTORONTO, August 11, 2015 – Legworks‘ next-generation prosthetic knee took first place in Ontario Centres of Excellence’s (OCE’s) Parapan Am Games-affiliated Accessibility Tech Pitch competition. The company immediately said it would use the $20,000 award to fit 200 amputees in developing countries with its device.

Legworks was selected from 18 participants in a two-day elimination pitch competition – one of the features of the Government of Ontario’s Accessibility Innovation Showcase held at MaRS Discovery District from August 8 to 10, 2015.

TechVibes and Metro News covered this announcement.

Legworks was one of five companies to make it to the final round of the competition.

BresoTec company logoOther finalists were Eightfold Technologies, MyndTec, BresoTec Inc., and Komodo OpenLabs. BresoTec Inc., formerly known as ApneaDx Inc., is a MaRS Innovation start-up company spun-off in partnership with the University Health Network’s Toronto Rehabilitation Institute and is developing a medical device to allow patients to determine whether they have sleep apnea without having to visit a sleep clinic.

Continue Reading

Law firm partners with UTEST program to offer legal advice to early-stage startups

TORONTO, ON (August 10, 2015) — Toronto-based law firm Aird & Berlis LLP (A&B) has become the sponsoring legal partner to the University of Toronto Early-Stage Technology Program (UTEST).

This partnership was covered in TechVibes, Law Times and the Financial Post‘s Legal Post blog.

Welcome to the table: Aird & Berlis are joining MaRS Innovation and the University of Toronto in supporting UTEST, an early-stage incubator for start-up companies that has graduated 17 companies and counting.
Welcome to the table: Aird & Berlis are joining MaRS Innovation and the University of Toronto in supporting UTEST, an early-stage incubator for start-up companies that has graduated 17 companies and counting.

UTEST is a 12-month incubation and acceleration program co-managed by the University of Toronto (U of T) and MaRS Innovation that allows selected U of T-affiliated early-stage startup companies to incorporate, use office space, receive mentorship and access $30,000 in funding, with opportunities for follow-on funding from MaRS Innovation.

In 2014, UTEST was named one of Canada’s most promising start-up accelerators in an online series by BetaKit, a digital publication that covers Canadian technology.

“We are thrilled to partner with A&B and leverage their legal expertise for our startups and emerging companies,” said Kurtis Scissions, who co-directs UTEST with MI’s Mike Betts. “To date, 17 companies, including Granata Decision Systems, Whirlscape, Crowdmark, eQOL and TrendMD, have successfully graduated from our program. We look forward to adding A&B’s Startups Team of lawyers to our mentorship group for the UTEST program, beginning in 2015.”

Continue Reading

MaRS Innovation featured in International Innovation magazine

International Innovation feature on MIMaRS Innovation and its member institutions are is profiled in International Innovation‘s July issue (#191) in a feature interview with Dr. Rafi Hofstein, MI’s president and CEO, written by Rosemary Peters.

The article is posted on the publication’s website and viewable through a digital interface (pages 80 and 81).

Here’s an excerpt from Dr. Hofstein’s comments:

“Canada’s academic research community is internationally highly competitive, but it has been argued that its scientific commercial success tags behind other countries such as the U.S. and the U.K. While this remains a matter of debate, I do agree that we need to continually encourage additional sources of seed capital to join is so as to allow for accelerated advancement of early-stage technologies. Industry needs to become much more engaged in advancing early-stage (and promising!) technologies emerging from the academic sector, which are usually young and in significant attention, navigation, management expertise and seed capital provisions. These are areas of rising importance in Canada, as many innovations fall into the ‘valley of death’ due to a lack of proper funding, or they leave the country and flourish in the U.S. where funding is more abundant.

Continue Reading
Back To Top